The current price of AXGN is $50.02 — it has increased by 2.61% since the previous close. Data as of Nov 6, 2026.
AXGN is up 1.13% over the past week, up 38.79% over the past month and up 112.22% over the past year. The price is above its 200-day moving average of $40.02.
Analysts' average 12-month price target for AXGN is $58.13, which implies 16.21% upside from the current price. Individual estimates range from $53.00 to $65.00.
Of the 11 analysts covering AxoGen, Inc., 2 rate it a strong buy and 9 rate it a buy. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.
AxoGen, Inc. has a market capitalization of $2.99B. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.
In its most recent quarterly report, AxoGen, Inc. posted earnings of $0.21 per share against an estimate of $0.1313, beating expectations by 59.94%. Upcoming reports are listed in the earnings calendar.
AxoGen, Inc. reported revenue of $75.83M in its most recent quarter, which has increased by 26.22% compared with the same quarter a year earlier. Analysts had expected $73.45M.
AxoGen, Inc. has not paid any dividends over the past year.
Companies most comparable to AxoGen, Inc. include MiMedx Group, Inc., Humacyte, Inc., Organogenesis Holdings Inc., Xtant Medical Holdings, Inc. and TELA Bio, Inc.
In the latest trading session AXGN moved between $48.14 and $50.13, a range of 3.98% of its current price.
Over the past 52 weeks AXGN has traded between $23.00 and $52.91. The current price is 5.46% below its 52-week high.
Figures as of Nov 6, 2026. This information is provided for general purposes only and is not investment advice.